未登录

H

Henrik Gréen

Linköping University

H指数:33

被引数:3,830

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anomaly detection as a tool for identifying cases of interest in postmortem toxicology

作为一种识别法医毒理学中感兴趣案例的工具的异常检测

Scientific Reports

IF3.9

2026-08-170

OAAI

Genomic Medicine Sweden: Advancing precision medicine at the national level

瑞典基因组医学：在国家层面推进精准医学

Journal of Internal Medicine

IF9.2

2026-07-280

OAAI

Anders Edsjö; Anna Lindstrand; Panagiotis Baliakas; David Gisselsson; Paula Mölling; Mia Wadelius; Åsa Johansson; Hannes Olauson; Hans Ehrencrona; Lovisa Lovmar; Christian G. Giske; Henrik Green; Ann Nordgren; Fulya Taylan; Martin Hallbeck; Erika Tång Hallbäck; Anna Green; Markus Heidenblad; Kina Höglund; Anders Jemt; Carl Mårten Lindqvist; Maria Johansson Soller; Magnus Sabel; Colum Walsh; Hartmut Vogt; Craig E. Wheelock; Martin Bergö; Jens Enoksson; Ann Ekberg Jansson; Cecilia Fagerström; Jan Holgersson; Stephanie Anja Juran; Mats G. Karlsson; Frida Lundmark; Eva Tiensuu Janson; Andreas Muranyi Scheutz; Malin Sund; Päivi Östling; Sofia Gruvberger-Saal; Marene Landström; Malin Melin; Lars Palmqvist; Richard Palmqvist; Bianca Stenmark; Anna Wedell; Malin Karnå; Katarina Nyström; Tobias Strid; Per Sikora; Maria Johansson; Therese Fagerqvist; Mirja Carlsson Möller; Oskar Frisell; Mats Ulfendahl; Mikaela Friedman; Lucia Cavelier; Valtteri Wirta; Thoas Fioretos; Richard Rosenquist

Synthetic cannabinoid receptor agonists inhibit the cardiac voltage-gated potassium channel hERG

合成大麻素受体激动剂抑制心肌电压门控钾通道hERG

Acta Pharmacologica Sinica

IF8.4

2026-07-210

OAAI

Do assay parameters affect the inter-assay comparability of cannabinoid CB1 receptor affinity and activation measurements?

测定参数是否影响大麻素CB1受体亲和力及活化测量的不同批次间可比性？

Toxicology and Applied Pharmacology

IF3.4

2026-07-010

OAAI

In Vitro Metabolism of Δ8-, Δ9-, and Δ10-THC in Human Hepatocytes: Distinct Δ10-THC Biotransformation and Implications for Drug Testing

体外Δ8-、Δ9-和Δ10-THC在人类肝细胞中的代谢：独特的Δ10-THC生物转化及其在药物检测中的意义

Drug Testing and Analysis

IF2.7

2026-06-020

OAAI

Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam

新型苯二氮䓬类药物乙溴唑拉姆的全球出现及其与γ-氨基丁酸A型（GABAA）受体的相互作用

Archives of Toxicology

IF6.9

2026-05-200

OAAI

Predicting affinity and potency of new psychoactive substances at cannabinoid 1 receptor with explainable artificial intelligence

用可解释的人工智能预测新精神活性物质对大麻素1受体的亲和力和效力

Frontiers in Pharmacology

IF4.8

2026-05-200

OAAI

Human-to-Rat Validation of PMI Biomarkers: A Bidirectional Cross-Species Metabolomics Study Reveals Asymmetric Translation

人致大鼠验证PMI生物标志物：一项双向跨物种代谢组学研究揭示不对称翻译

Analytical Chemistry

IF6.7

2026-05-110

PRE

Development and analytical validation of a targeted short-read next generation sequencing-based pharmacogenetic panel for comprehensive variant detection

靶向短读下一代测序为基础的药物基因组学面板的开发与分析验证，用于全面变异检测

British Journal of Pharmacology

IF7.7

2026-05-050

OAAI

5-HT2A receptor agonism by tert-leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

特亮氨酸酰胺和缬氨酸酰胺合成大麻素对5-HT2A受体的激动作用：体外和体内证据

British Journal of Pharmacology

IF7.7

2026-05-050

OAAI

Fatal intoxications with nitazenes: postmortem findings, toxicology, and in vitro characterization at the μ-opioid receptor of six nitazene analogues

氮杂卓类物质致死性中毒：尸体检验结果、毒理学分析及六种氮杂卓类同系物在μ-阿片受体上的体外表征

Archives of Toxicology

IF6.9

2026-04-250

PRE

In vitro metabolomics for the characterization of drugs of abuse and new psychoactive substances in SH-SY5Y cells

体外代谢组学用于鉴定滥用药物和新精神活性物质在SH-SY5Y细胞中的特性

Environmental Toxicology and Pharmacology

IF4.2

2026-04-120

OAAI

In vitro γ-aminobutyric acid A (GABAA) receptor activity and binding interactions at the α+/γ2– interface of 53 prescription and designer benzodiazepines

体外γ-氨基丁酸A（GABAA）受体活性及在53种处方和设计苯二氮䓬类药物的α+/γ2–界面处的结合相互作用

Communications Chemistry

IF6.2

2026-04-070

OAAI

The human metabolome and machine learning improves predictions of the post-mortem interval

人类代谢组学和机器学习提高了死亡时间预测的准确性

Nature Communications

IF15.7

2026-02-110

OAAI

Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathy

肥厚型心肌病瑞典队列患者表型的遗传决定因素

Scientific Reports

IF3.9

2025-11-100

OAAI

Structure-activity relationship of prevalent synthetic cannabinoid metabolites on hCB1 in vitro and in silico dynamics

常见合成大麻素代谢物的构效关系及其对hCB1的体外和计算机模拟动力学研究

Acta Pharmacologica Sinica

IF8.4

2025-11-030

OAAI

In vitro monoamine reuptake inhibition and forensic case series in Sweden of the synthetic cathinones 2-, 3-, and 4-Me-alpha-PiHP

体外单胺再摄取抑制作用及瑞典法医学案例系列中合成的卡西酮类物质2-, 3-, 和 4-Me-alpha-PiHP

FORENSIC SCIENCE INTERNATIONAL

IF2.5

2025-09-010

OAAI

Setup and Evaluation of the TRACT Assay Principle for the In Vitro Functional Characterization of Modulators of the Serotonin Transporter and the Serotonin 2A Receptor

建立和评估用于体外功能表征血清素转运蛋白和血清素2A受体调节剂的TRACT分析法原理

Analytical Chemistry

IF6.7

2025-08-060

PRE

Pharmacogenomics in pediatric oncology patients with solid tumors related to chemotherapy-induced toxicity: A systematic review

实体瘤儿童肿瘤患者化疗诱导毒性与药物基因组学的关系：一项系统综述

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2025-07-010

OAAI

Structure-metabolism relationships of 4-pentenyl synthetic cannabinoid receptor agonists using in vitro human hepatocyte incubations and high-resolution mass spectrometry

4-戊烯基合成大麻素受体激动剂的构效关系研究：采用体外人肝细胞孵育和高分辨率质谱法

ARCHIVES OF TOXICOLOGY

IF6.9

2025-05-200

OA